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In previous reports, patients with Ewing’s sarcoma received radiation therapy (XRT) for deﬁnitive local control because metastatic
disease and pelvic location were thought to preclude aggressive local treatment. We sought to determine if single-site metastatic
diseaseshouldbetreateddiﬀerentlyfrommulticentric-metastaticdisease.WealsowantedtoreinvestigatetheimpactofXRT,pelvic
location, and local recurrence on outcomes. Our results demonstrated a signiﬁcant diﬀerence in overall survival (OS) between
patientswitheitherlocalizeddiseaseorasingle-metastaticsiteandpatientswithmulticentric-metastaticdisease(P = 0.004).Local
controlwasalsofoundtobeanindependentpredictorofoutcomesasdemonstratedbyasigniﬁcantdiﬀerenceinOSbetweenthose
with and without local recurrence (P = 0.001). Axial and pelvic location did not predict a decreased OS. Based on these results,
we concluded that pelvic location and the diagnosis of metastatic disease at diagnosis should not preclude aggressive local control,
except in cases of multicentric-metastatic disease.
1.Introduction
Ewing’ssarcoma(EWS)isthesecondmostcommonprimary
bone tumor in children and adolescents [1–6], representing
3% of all pediatric malignancies [2, 5, 7]. Most arise
from bone, but extraosseous EWS may occur [2]. Stage
and tumor size have consistently been shown to be inde-
pendent predictors of survival [8–12]. Additional factors
traditionally thought to be prognostic of decreased survival
are pelvic location, advanced age, and histological response
to chemotherapy [2, 10, 13]. However, with improvement
in treatment protocols and chemotherapy regimens, these
factors deserve reinvestigation [2].
Despite advances in chemotherapy protocols, survival
rates are consistently in the 54–68% range [8, 9, 12, 14, 15].
This plateau in the improvement of outcomes has been
frustrating despite chemotherapy trials, new regimens, and
dose intensiﬁcation [5, 7, 14, 16]. Therefore, it is important
to reinvestigate the impact of local control on overall
survival. Previous studies, in which up to 80–90% of patients
received radiation therapy (XRT) for local control with or
without surgery, have shown that XRT alone for local control
is associated with poor outcomes [8, 12, 17]. Many patients
received XRT for local control because metastatic disease
and pelvic location were thought to preclude aggressive local
treatment [7, 14, 18–20].2 Sarcoma
The primary goal of this study was to investigate the
clinical results of Ewing’s sarcoma treated at our institution,
where a smaller percentage of patients have received radia-
tion for local control compared to previous studies. Our goal
was to determine (1) if axial tumors have worse outcomes
than appendicular tumors, (2) if there is a survival diﬀerence
between multicentric metastatic EWS and metastases to a
single location, (3) the eﬃcacy of XRT for local control in
terms of survival and complications, and (4) if there is a
survival diﬀerence between osseous and extraosseous EWS.
2. Methods
After Institutional Review Board approval, we performed
a retrospective review of all patients with the diagnosis of
EWS treated at our tertiary musculoskeletal oncology center
from 1981 to 2009. We reviewed patients’ medical records
for surgical reports, radiographic studies, and pathological
results in order to determine primary location, AJCC stage
at diagnosis, neoadjuvant treatment, primary local treat-
ment, adjuvant treatments, local recurrence, late-metastatic
disease, and late complications. For those patients that
underwent surgical resection of a primary lesion, margins
were described as negative or positive on the basis of review
of pathologic analysis, and all complications were recorded.
Patients were excluded for insuﬃcient followup (<2
years), except in the case of mortality prior to 2-year fol-
lowup. Both osseous and extraosseous EWS were included
for review. Length of followup, time to recurrence, and time
to late metastases were calculated based on the date of diag-
nosis.
Forty-six patients treated between 1981 and 2009 were
included with an average and median followup of 5.9 years
and 3.5 years (range 0.2–29.8 years), respectively.
Kaplan-Meier survival curves were created for overall
survivalaswellaseventfreesurvival.LogRank(Cox-Mantel)
test was used to determine statistical signiﬁcance between
survival curves. Multivariate Cox Regression was used to
determine independent covariates. Chi-square analysis was
used to determine correlation between variables. Statistical
analyses were conducted with PASW Statistics 18 and 19
(IBM SPSS, IBM Corporation, Somers, NY).
3. Results
Forty-sixpatientstreatedbetween1981and2009(with32/46
(70%) after 1998) were included with adequate followup
or mortality. Only 5/46 (11%) patients were diagnosed
prior to 1992. Patient characteristics are shown in Table 1.
The average and median ages at diagnosis were 22 and 17
years (range 2–40 years), respectively, with 9 (20%) patients
younger than 14 years of age. The male to female ratio was
1.6. Location was axial in 19/46 (41%) of primary lesions,
with 11/46 (24%) pelvic lesions. Metastatic disease at the
time of diagnosis was found in 13/42 (31%) of patients
(AJCC stageatdiagnosis wasunknown forﬁvepatients), and
7/42 (17%) of patients presented with multicentric disease.
Lung/mediastinum was the only location of single site
Table 1: Patient characteristics.
Variable (#)† Number/percentage
Age (46)
<14 9 (20%)
≥14 37 (80%)
Sex (46)
Male 28 (61%)
Female 18 (39%)
Location (46)
Appendicular 27 (59%)
Axial 19 (41%)
Pelvic (46)
No 35 (76%)
Yes 11 (24%)
Bone or soft tissue (46)
Bone 39 (85%)
Soft tissue 7 (15%)
Metastatic disease (42)
No 29 (69%)
Yes 13 (31%)
Multicentric disease (42)
No 35 (83%)
Yes 7 (17%)
Neoadjuvant chemotherapy (43)
No 6 (14%)
Yes 37 (86%)
Local radiationδ (43)
No 33 (77%)
Yes 10 (23%)
Margins (35)
Negative 26 (74%)
Positive 9 (26%)
Local recurrence (46)
No 31 (67%)
Yes 15 (33%)
Late metastatic disease (44)
No 24 (55%)
Yes 20 (45%)
Status at last followup (46)
AWOD 23 (50%)
AWED 6 (13%)
DOD 16 (35%)
DWOD 1 (2%)
AWOD: alive without disease.
AWED: alive with evidence of disease.
DOD: died of disease.
DWOD: died without evidence of disease.
†: number of patients with suﬃcient data for each data point.
δ: local radiation either as primary local treatment of neoadjuvant.
metastatic disease in our series (Table 2). The treatment to
the metastatic site in these six patients was radiation in three
patients, none in two patients, and one patient underwentSarcoma 3
Table 2: Data for patients with single-site metastatic disease.
Patient Primary location Metastatic location Treatment to metastatic
location
Outcome at latest
followup
1 Femur Lung Radiation DWODδ
2 Femur Lung Radiation AWOD
3 Femur Lung None AWOD
4 Clavicle Lung None DOD†
5 Femur Lung/mediastinum Thoracotomy AWOD
6 Ilium Lung Radiation AWOD
AWOD: alive without disease.
AWED: alive with evidence of disease.
DOD: died of disease.
DWOD: died without evidence of disease.
δ: Patient died as result of radiation lung injury.
†: Patient died at greater than six years from diagnosis.
thoracotomywithresection.Neoadjuvantchemotherapywas
given in 38 patients, ﬁve patients did not receive neoadjuvant
chemotherapy prior to index surgical resection, and data was
insuﬃcient for three patients. One patient with a chest wall
mass that was incompletely excised at an outside institution
received neoadjuvant chemotherapy prior to complete chest
wall resection at our institution.
Surgical resection of the primary lesion was attempted
in 38/45 (84%) patients. Twenty-six (74%) of these had
negative margins (margin status was not available on
three patients). Orthopaedic oncologists performed 32/38
(84%) resections. Limb salvage, and no amputations were
performed at the index procedure. Patients that received
surgical resection after radiation, resection for recurrence of
EWS after XRT, or resection after biopsy were included as
surgical resections. Seven patients did not undergo surgical
resection, and one patient did not have suﬃcient primary
treatmentdata.OnepatientwiththoracicEwing’sunderwent
laminectomy for evolving lower extremity paralysis without
goal of complete resection; this was not considered surgical
treatment for primary location. One patient underwent
chest wall resection after an incompletely resected chest wall
tumor increased in size despite chemotherapy. This chest
wall resection performed at our institution was considered
the index procedure for our data. Nine patients underwent
resection of pelvic EWS with negative margins achieved in
ﬁveofnine(56%)(Table 3).Twoofthepatientswithpositive
margins had recurrence or residual disease after XRT. The
remaining two patients with positive margins had resections
at an outside institution or by an orthopaedic spine surgeon.
Five of eleven (33%) had died of disease at latest followup.
Four of the ﬁve patients that died of disease had received
XRT. The other patient that died of disease had multicentric
metastatic disease at presentation and had an index surgery
at an outside hospital without neoadjuvant or adjuvant
chemotherapy.
Radiation was used for local control in only 10/43 (23%)
of patients (three patients had insuﬃcient data) (Table 4).
Four patients who received radiation treatment for deﬁnitive
local control had metastatic disease at diagnosis; two of these
patients had multicentric-metastatic disease. Five patients
underwent resection for residual disease or local recurrence
after XRT. One patient that received preoperative XRT
followed by resection eleven months after diagnosis, which
showed residual tumor cells, was not considered a recur-
rence. Another patient underwent resection for recurrence
of EWS that was found on bone scan more than two years
after diagnosis, resulted in a few small areas of viable tumor.
One patient developed a likely radiation-induced sarcoma
(a high-grade retroperitoneal sarcoma with myoﬁbroblastic
phenotype and EWS translocation negative) at the site of
radiation ten years after deﬁnitive local XRT. Complications,
local recurrence, or radiation sarcoma occurred in seven
of ten (70%) of patients treated with radiation. Chi-square
analysis failed to show a signiﬁcant correlation between local
treatment with radiation and recurrence or complications.
Treatment failure was determined by event free survival
(EFS). An event was deﬁned as any local recurrence, late
metastases, or death from disease. The local recurrence
rate was 33% (15/46) and late metastases occurred in 45%
(20/44) (Table 1). The average time from diagnosis till local
recurrence was 1.65 years (Table 5). The one patient that
developed radiation sarcoma was not included as a recur-
rence. The 5- and 10-year EFS was 52% and 38%. Age ≥ 14
(P = 0.021), multicentric metastatic disease at diagnosis
(P = 0.002), and soft tissue Ewing’s sarcoma (P = 0.020)
exhibited signiﬁcant eﬀect on EFS according to Log Rank
univariate analysis. Axial location, pelvic location, metastatic
disease, local control with radiation, and margin status
were not signiﬁcant (Table 6). Only multicentric-metastatic
disease(P = 0.007)andanextraosseousprimary(P = 0.014)
remained signiﬁcant with Cox regression multivariate analy-
sis (Table 7). Margin status was not included in multivariate
analysis as it was not signiﬁcant in univariate analysis, and
two of seven patients with multicentric-metastatic disease
would be excluded from multivariate analysis for lacking
margin status at resection. Chi-square analyses did not show
a signiﬁcant correlation between pelvic location and tumor
size or metastatic disease at presentation.
Atlatestfollowup,50%(23/46)werealivewithoutdisease
(AWOD), 13% (6/46) were alive with evidence of disease
(AWED), 35% (16/46) had died of disease (DOD), and 2%4 Sarcoma
Table 3: Data for patients with pelvic location EWS.
Patient Location Chemotherapy Radiation Surgery Margin Local
recurrence Outcome
1 Right
hemipelvis Insuﬃcient data Insuﬃcient data Right internal
hemipelvectomy Negative None Died of disease
2 Right superior
ramus/ischium Yes Yes Excision
superior ramus Positive Yes Died of disease
3S a c r a l / S 5 Y e s N o Resection S3–5,
coccyx Negative None Alive without
disease
4 Right superior
ramus Yes No Right internal
hemipelvectomy Negative None Alive without
disease
5 Right ilium Yes No Right internal
hemipelvectomy Negative None Alive without
disease
6L e f t i l i u m Y e s Y e s
Left internal
hemipelvectomy
for recurrence
after radiation
Positive Yes Died of disease
7 Sacral/S1-S2 No No
Laminectomy
S1-S2/resection
tumor
Positive None Alive with evidence
of disease
8 Right ilium Yes Yes Insuﬃcient data Insuﬃcient
data None Alive without
disease
9 Right ilium Yes Yes Insuﬃcient data Insuﬃcient
data None Died of disease
10 Pelvis
(ST/ovary) No No TAH-BSO at
OSH Positive Yes Died of disease
11 Right ilium Yes No Right internal
hemipelvectomy Negative None Alive without
disease
ST: soft tissue EWS.
(1/46) had died without disease (DWOD) (Table 1). The
patient that died without evidence of disease, died second to
radiation, for treatment of metastatic location, lung injury
in the pediatric intensive care unit. Only one other patient
withsinglesitemetastaticdiseasedied,andthiswasatgreater
than six years after diagnosis. Four of the six (67%) of
the patients with single site metastatic disease were AWOD
at latest followup (Table 2). Overall survival calculation
included both DOD and DWOD. The 5- and 10-year overall
survival (OS) was 68% and 55%. The OS for the thirty-four
patients with either localized disease or a single metastatic
site was 73% at ﬁve years. The OS for the seven patients
with multicentric-metastatic disease was signiﬁcantly worse
at 21% (P = 0.004) (Figure 1). The ﬁfteen patients who
sustained a local recurrence had a signiﬁcantly worse 5-
year OS (34% versus 83% for those without recurrence,
P = 0.001) (Figure 2). Only one of ﬁfteen patients (7%)
with local recurrence was alive without evidence of disease
at latest followup (Table 5). Age ≥ 14, axial location, pelvic
primary, soft tissue primary, metastatic disease at diagnosis,
localradiation,andmarginstatuswerenotfoundtopredicta
pooroutcomebyLogRankunivariateanalyses(Table 8).Cox
regression multivariate analyses showed that multicentric-
metastatic disease (P = 0.0291) and local recurrence (P =
0.0002) remained independent predictors of overall survival
(Table 9). Margin status was not included in multivariate
analysis as it was not signiﬁcant in univariate analysis, and
two of seven patients with multicentric metastatic disease
would be excluded from multivariate analysis for lacking
margin status at resection.
4. Discussion
Reports of overall 5-year survival for Ewing’s sarcoma range
from 57–77% [1, 5, 12, 14, 21]. Survival rates for localized
disease are increased to 73–84% [3, 7, 22, 23]. Multiple
large studies have consistently shown that tumor size and
stage are important prognostic factors for overall survival
with Ewing’s sarcoma [8–10, 12]. In a more recent study
with a 5-year EFS of 55.1% and a 5-year OS of 63.5%,
Rodr´ ıguez-Galindoetal.conﬁrmedthattumorsizeandstage
were independent predictors of event free (EFS) and overall
survival (OS) [8, 9]. Our study demonstrated similar 5-
year EFS and OS with 52% and 68%, respectively, but we
demonstrated that multicentric-metastatic disease and not
the mere presence of metastatic disease was signiﬁcant.
Location has consistently gained attention both as a
prognostic variable and for local treatment determination.
Axial and especially pelvic primary locations have been
found to be prognostic of poorer survival with rates 18–
51% [10, 14, 15, 20, 24]. Many of these studies included
patients from older treatment eras with more of an emphasis
on radiation. Shankar et al. in a study of 191 patients with
localized Ewing’s treated from 1987–1993 concluded thatSarcoma 5
Table 4: Data for patients treated with radiation for sole local control or neoadjuvant therapy prior to surgical resection.
Patient Primary location Year of
diagnosis
Metastatic disease
at diagnosis
Surgical
resection after
XRT
Recurrence
(year) Complication
Radiation-
induced
sarcoma
1 Femur 1981 None Yes/for
recurrence Yes (1983) None None
2 Femur 1983 Lung None None Radiation
necrosis femur None
3 Deltoid (ST) 1985 None
Yes/forequarter
amputation for
recurrence
Yes (1986) None None
4 Ischium/ramus 1998 Multicentric Yes Yes (1999) None None
5 ilium 2000 None None None None Yes
6 ilium 2001 None None None None None
7 Thoracic/
mediastinum 2001 None None None Radiation
esophagitis None
8 Femur 2005 Lung/mediastinum Yes None None None
9 Tibia 2006 Mulitcentric None None None None
10 Ilium 2007 None Yes/for
recurrence Yes (2009) None None
ST: soft tissue EWS.
Table 5: Data for patients with local recurrence.
Patient Location Local control
Time till
recurrence
(years)†
Treatment for recurrence Outcome
(at latest followup)
1 2nd Metatarsal Surgery 2.3 Ifosfamide, Carboplatinum, Etoposide Alive with evidence of
disease
2 Chest wall Surgery 6 Resection Died of disease
3 Deltoid (ST) Radiation 1.2 Forequarter amputation Died of disease
4 Femur Surgery 3.1 Reinduction chemotherapy/Distal femur
resection Died of disease
5C h e s t w a l l
Surgery/(initial surgery:
incomplete resection at
OSH)/then chest wall
resection for increasing size
while on chemotherapy
0.7 None Died of disease
6 Chest wall Surgery 1.2 Resection/Cytoxan/Topotecan Died of disease
7 Pelvic/ovary
(ST) Surgery 0.1 None Died of disease
8 Thigh Surgery 0.2 Resection/Vincristine/Doxorubicin/
Cyclophosphamide Died of disease
9 Clavicle Surgery 2.4 Resection/Ifosfamide/Etoposide/
Cytoxan/Topotecan
Alive with evidence of
disease
10 Femur Surgery 0.9 None Died of disease
11 Popliteal (ST) Surgery 2.8 Above knee amputation Alive with evidence of
disease
12 Pelvis Radiation/surgery 1 None Died of disease
13 Femur Radiation 2.2 Proximal femur resection Alive without
evidence of disease
14 Pelvis Radiation 1.4 Hemipelvectomy/Cytoxan/Topotecan/XRT Died of disease
15 Humerus Unknown 2.1 Shoulder disarticulation Alive with evidence of
disease
†: Time to recurrence calculated from date of diagnosis.
ST: soft tissue Ewing’s.6 Sarcoma
Table 6: Univariate analyses of variables for Event free survival
(EFS).
Univariate event free survival analysisδ
Variable
5-year
cumulative
survival
P Value
Age (46 patients) 0.021†
<14 0.78 ±.14
≥14 0.46 ±.09
Location (46 patients) 0.164
Appendicular 0.57 ±.10
Axial 0.45 ±.12
Pelvic location (46 patients) 0.796
No 0.54 ±.09
Yes 0.48 ±.16
Metastatic disease (42 patients) 0.150
No 0.61 ±.09
Yes 0.29 ±.15
Multicentric metastatic disease
(42 patients) 0.002†
No 0.61 ±.09
Yes 0.00 ±.00
Bone or soft tissue (46 patients) 0.020†
Bone 0.56 ±.08
Soft tissue 0.29 ±.17
Local radiation (43 patients) 0.675
No 0.54 ±0.09
Yes 0.40 ±0.16
Margins (35 patients) 0.337
Negative 0.60 ±.10
Positive 0.28 ±.21
δ: Log Rank of Kaplan Meier EFS survival curves.
†: Statistically signiﬁcant factor.
pelvic tumors had a worse outcome. In their study, 15%
of localized disease of long bones received radiation only
compared to 74% of localized disease of the pelvis with a
47% relapse rate for all localized pelvic disease regardless of
treatment [23]. Only four of eleven (36%) of patients with
pelvicdiseaseinourseriesreceivedradiationforlocalcontrol
(Table 3).
Rodriguez-Galindo et al. reported that tumor location
has not shown the same signiﬁcance with improved newer
treatments [2]. J¨ urgens et al. and Wunder et al. found
no relationship between pelvic site and event free survival
[11, 25]. Even in studies of patients with only localized
disease, the site of primary lesion was not prognostic, only
the size, white blood cell count, and histological response
to chemotherapy predicted EFS [3, 26]. More recent studies
have supported that pelvic and/or axial locations alone were
not associated with an increased local failure or decreased
overall survival [8, 9].
These eﬀects are due in part to an increased emphasis
on surgical control and improved techniques. In a study
Table 7: Determination of independent variables for Event Free
Survival (EFS) with multivariate Cox regression analysis.
Multivariate Cox Regression EFS analysis of covariates
Variable HR 95% CI P value
Age 0.638
<14 1.00
≥14 1.56 0.26–8.56
Location 0.165
Appendicular 1.00
Axial 2.22 0.72–6.85
Multicentric metastatic disease 0.007†
No 1.00
Yes 4.16 1.47–11.81
Bone or soft tissue 0.014†
Bone 1.00
Soft tissue 5.19 1.40–19.23
Local radiation 0.397
No 1.00
Yes 1.55 0.56–4.27
†: statistically signiﬁcant independent variable on event free survival.
dedicated to stage IIB pelvic Ewing’s sarcoma, Yang et al.
reported an increased overall survival of 51% with surgical
resection compared to 18% without surgical resection [24].
Frassica et al. showed an increased OS of 5 years with
resection over radiation alone (75% versus 25%) [20]. A
pelvic 5-year OS rate of 64% and EFS of 48% in our series
likely reﬂects improved local control methods with surgery
and a later treatment era as none of our eleven pelvic tumors
were diagnosed before 1992 and only four received prior
radiation. Those patients that received radiation represented
three of ﬁve patients that died of disease (Table 3).
Multiple studies and reports have repeatedly concluded
that metastatic disease at the time of diagnosis is predictive
of poorer outcomes [5, 8–10, 15]. The large European Inter-
groupstudyof975patientsshowedasigniﬁcantdiﬀerencein
relapse free survival between patients with localized disease
(55%) and those with metastatic disease at presentation
(21%) [10], which is similar to our results with EFS 61%
and 29% respectively. However, this result for us was not
signiﬁcant, probably due to study size limitations.
Multiple studies have demonstrated improved survival of
pulmonary metastatic disease over extrapulmonary metas-
tases [2, 8–10, 27]. Cotterill et al. demonstrated with
univariate log rank analysis a signiﬁcant diﬀerence between
lung metastases and lung and bone metastatic disease [10].
However,multivariateanalysiswasnotusedtodeterminethe
independent eﬀects on outcomes of metastatic location or
single versus multicentric-metastatic disease. Wunder et al.
foundsimilarresultstoours,withnosigniﬁcantdiﬀerencein
outcomes between localized and metastatic disease, but none
of the patients had multifocal osseous lesions. Outcomes of
patients with metastatic disease were linked to the degree of
necrosis of the primary site [25]. We have shown that when
multicentric-metastatic disease was the only independentSarcoma 7
Table 8: Univariate analyses of variables for Overall Survival (OS).
Univariate Overall Survival Analysisδ
Variable
5-year
cumulative
survival
P Value
Age (46 patients) 0.217
<14 0.74 ± .16
≥14 0.67 ± .08
Location (46 patients) 0.308
Appendicular 0.67 ± .10
Axial 0.68 ± .11
Pelvic Location (46 patients) 0.455
No 0.69 ± .09
Yes 0.64 ± .15
Bone or Soft Tissue (46
patients) 0.066
Bone 0.72 ± .08
Soft Tissue 0.43 ± .19
Metastatic Disease (42
patients) 0.061
No 0.70 ± .09
Yes 0.51 ± .15
Multicentric Metastatic
Disease (42 patients) 0.004†
No 0.73 ± .08
Yes 0.21 ±.18
Local Radiation (43 patients) 0.398
No 0.70 ± .09
Yes 0.50 ± .16
Recurrence (46 patients) 0.001†
No 0.83 ± .07
Yes 0.34 ± .14
Margins (35 patients) 0.291
Negative 0.75 ±.09
Positive 0.53 ±.17
δ: Log Rank of Kaplan Meier OS survival curves.
†: Statistically signiﬁcant factor.
predictor of both EFS and OS, and when patients with
multicentric disease were selected out, the 5-year OS and
EFS of patients without or a single metastatic location
were 73% and 61%, respectively. According to Rodriguez-
Galindo et al., there is a spectrum of metastatic disease from
apparent localized disease with micrometastases to single-
site metastatic disease to multicentric-metastatic disease [2].
Metastatic disease at presentation is important, but, perhaps,
aggressive local control eﬀorts should not be abandoned in
cases of single-site metastatic disease. Local treatment to the
site of metastatic disease in those patients with single-site
metastatic disease should be further investigated in future
studies. Questions that remain to be answered include, does
XRTorsurgicalresectionyieldbetteroutcomesanddoessize
or number of lung metastases matter?
Table 9: Determination of independent variables for Overall Sur-
vival (OS) with multivariate Cox regression analysis.
Multivariate Cox Regression OS analysis of covariates
Variable HR 95% CI P value
Age 0.8703
<14 1.00
≥14 0.87 0.16–4.63
Metastatic disease 0.6000
No 1.00
Yes 1.57 0.29–8.35
Multicentric-metastatic
disease 0.0291†
No 1.00
Yes 8.23 1.24–54.64
Bone or soft tissue 0.2187
Bone 1.00
Soft tissue 2.33 0.61–8.95
Local recurrence 0.0002†
No 1.00
Yes 11.64 3.24–41.74
†: statistically signiﬁcant independent variable on overall survival.
The role of local control has increasingly become impor-
tant as a plateau has been reached with current chemother-
apeutic regimens. Our local recurrence rate of 33% in an
average of 1.65 years is in the wide range of published
rates of 7–52% in 1.7–2.3 years [11, 14, 17, 20, 22, 25–
30]. Recurrence rates for studies of only localized disease
range 5–29% [3, 20, 31]. Local failure has been shown to be
predicted by the treatment era, size of the primary tumor,
and the type of local control [8, 9]. While margin status was
not signiﬁcant, our study demonstrated that local control
is important for overall survival with local recurrence as an
independent predictor of overall survival (P = 0.0002). Our
Kaplan-Meier 5-year OS for patients with local recurrence
was 34% ± 14. Rodriguez-Galindo et al. reported a survival
of 21.7±7.8 for patients with local recurrence only [28]. Our
survival after local recurrence does not separate out patients
that had both local recurrence and late-distal metastatic
disease, but multivariate analysis demonstrated that the
presence of local recurrence independently predicts poor
survival (Table 9). Our outcomes data for patients with local
recurrence is likely even worse than represented by KM
survival curve as only one of ﬁfteen patients (7%) was alive
without disease at latest followup (Table 5).
Radiation therapy alone as deﬁnitive local control for
EWS has been found to correlate with increased local
recurrence and a higher complication rate [2, 8, 10–12, 27,
28]. In previous studies, up to 90% of patients received
radiation for primary local control [8, 17]. In the European
Intergroup Cooperative Study, eight of nine patients that
developed a secondary malignancy had received radiation
[10]. Radiation has often been reserved for more diﬃcult to
resect locations such as the pelvis [7, 14, 18–20]. Radiation
has also been preferred for local treatment in the presence8 Sarcoma
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Figure 1: Kaplan-Meier overall survival curves comparing patients with and without multicentric-metastatic disease at diagnosis. Log Rank
univariate analyses demonstrated signiﬁcance (P = 0.004).
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Figure 2: Kaplan-Meier overall survival curves comparing patients with and without local recurrence. Log Rank univariate analyses
demonstrated signiﬁcance (P = 0.001).Sarcoma 9
of metastatic disease. Craft et al. demonstrated that 55% of
patients with metastatic disease received radiation only for
local control [14]. In a large study by Rodr´ ıguez-Galindo
et al., radiation was found to be a signiﬁcant factor for
local control failure. Treatment era was also signiﬁcant, but
this likely also includes eﬀects of increased radiation use in
earlier treatment eras [8]. Rosito et al. showed that radiation
alone for local treatment was associated with an increased
local recurrence rate (15.3% versus 1.6%) [3]. Increased
recurrence after local control with radiation alone could be
attributed to the tumor’s hypoxic “core” that is relatively
radiation-resistant [17, 24]. In our study, radiation may
not have been shown as a signiﬁcant predictor of EFS or
OS because only 10/43 (23%) received radiation. However,
those patients that did receive radiation for local control
did have a high complication and local recurrence rate of
70%.
With advances in resection and reconstruction tech-
niques and technology, surgical resection for local control
has increased. Increases in survival and EFS can be explained
by more widespread utilization of surgical resection for
local control [3, 12]. Lee et al. found a signiﬁcant survival
advantage with surgical resection compared with radiation
alone [12]. Not only do the above studies indicate better
local control and improved survival with surgical resection,
but surgical resection of locally recurrent disease has been
shown to increase survival rates after local recurrence [28].
Survival was even increased for those patients with positive
margins after salvage resection [28], perhaps implicating a
role in reducing tumor burden as an adjunct to aggressive
salvage chemotherapy [32]. Similar results were shown in
pelvic tumors [24].
Historically, extraskeletal Ewing’s sarcoma has been
treated similarly to skeletal lesions [32] .S t u d i e sh a v eb e e n
conﬂicting regarding outcomes of these lesions [21, 27, 29,
33]. Pradhan et al. suggested that there was no survival
diﬀerence between skeletal and extraskeletal disease (64%
and 61% resp.) [27] .H o w e v e r ,A p p l e b a u me ta l .i nr e v i e w
of the United States surveillance, epidemiology, and end
results (SEER) database found a signiﬁcant 5-year overall
survival advantage for extraskeletal Ewing’s over skeletal
disease (69.7% versus 62.6%, P = 0.02) [33]. In the
present study, extraskeletal lesions did not demonstrate a
signiﬁcantly worse overall survival, but both univariate and
multivariate analyses identiﬁed extraosseous disease as a
signiﬁcant predictor of EFS as four of seven (57%) sustained
local recurrence and ﬁve of seven (71%) sustained late-
metastatic disease. An older study by Rud et al. from
Mayo Clinic demonstrated local recurrence (46%) and late-
metastatic disease (80%) rates similar to ours. Their study
included patients treated between 1935 and 1985, but even
whenpatientspriorto1970wereexcluded,the5-yearOSwas
only 48% [29]. Our overall EFS and OS may have been worse
than these other studies as only four of seven (57%) received
chemotherapy prior to resection. Perhaps the conﬂicting
outcomes for osseous and extraosseous outcomes warrants
further cytologic and molecular testing of these two similar
lesions.
5. Conclusion
Local control, marked by the eﬀect of local recurrence, does
play a signiﬁcant role in overall survival. The mere presence
ofmetastaticdiseaseatdiagnosisshouldnotprecludeaggres-
sive local control, except perhaps in cases of multicentric
metastatic disease. Pelvic disease oﬀers unique anatomical
challenges for resection and reconstruction, but we argue
that it should be approached with aggressive surgical local
control. Continued analyses of extraosseous lesions should
be conducted to determine how their biology diﬀers from
Ewing’s sarcoma of bone and if therapy should be tailored
to individual tumor biology.
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